5 December 2016

MR DENGUE, THE UNWANTED GUEST, AIMS TO MEET AS MANY MALAYSIAN AS POSSIBLE

PSA roadshow by The Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC) supported by Sanofi Pasteur cuts through the ‘white noise’ of dengue reporting to engage the public on good dengue prevention habits 
While DENGUE awareness is high, poor attitudes remain. The public run the risk of becoming immune to the impact of dengue infection on their lives, families and communities by treating them as ‘white noise.’ As recently as last month, public sentiment remains indifferent to dengue, a painful and debilitating disease that can affect quality of lives up to six weeks post recovery. “I have heard stories about dengue but we never really did anything about it at home because we did not think it would affect us,”2 is one current example of public response to dengue.

Enter MR.DENGUE, The Unwanted Guest, a public service awareness roadshow by The Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC) supported by Sanofi Pasteur. The campaign aims to cut through this ‘white noise’ of indifference through the use of satirical humour to catch the attention of the public on social media. Once he has your attention, he provides information about dengue fever, empowering the public with tools to protect themselves from the disease.

MR.DENGUE makes the invisible, visible. He represents the hidden dengue threat that is around all the time. It makes for playful education, and a more evocative portraiture of the disease which is a fresh way to communicate dengue prevention with the public,” said Baptiste De Clarens, Managing Director for SANOFI PASTEUR MALAYSIA, Singapore and Brunei. 

“Since the introduction of Mr. Dengue in February, he has been busy showing what he’s all about, what he will do to you.  He has also been sharing his "exploits" by hijacking twitter conversations and spreading his message of ‘mozzie domination’ on Facebook. Between April to July this year, the campaign garnered more than 2.7m impressions online, supported by initiatives with key media partners. And with the concourse roadshow here at Sunway Pyramid this weekend, we hope to reach out to many more Malaysians. Additionally, Malaysians can ‘meet’ Mr. Dengue by liking his Facebook page - www.facebook.com/mymrdengue. Spread the news about Mr. Dengue on your social media and he might just pay you a visit,” he added.

According to MSIDC (Malaysian Society of Infectious Diseases and Chemotherapy), Malaysians are still not doing enough on the dengue prevention front. “We know this from recent reports on public sentiment. Malaysians need to remember that dengue affects every one of us regardless of age, sex, health or economic status. Don’t wait until it happens to you or a family member before you take preventive action. Every 3 minutes, 1 person in Malaysia is infected3.  So please do not think you will not get dengue at some point in your life,” said Prof. Dr Zamberi Sekawi.

Everyone has a role to play in preventing dengue and protecting their families against the burden of the disease. Amongst the top tips shared by MSIDC and host and spokesperson for the Mr. Dengue campaign, Jason Leong during the media launch today were:

·         Practice vector control
o   Frequent clearing of stagnant water
o   Killing mosquitoes using insecticides
o   Use of tight-fitting lids or mesh on water storage containers
o   Solid waste management
·         Take steps to reduce risk of being bitten by an infected mosquito
o   Try to wear clothing that reduces skin exposure during daylight hours
o   Use repellents on exposed skin or clothing
o   Install mosquito nettings on windows
o  Insecticide aerosols, mosquito coils or other insecticide vaporisers and air conditioning can be used inside.

Also present at the media launch were representatives from the Ministry of Health and schoolchildren participating in the Dengue Patrol 2016 program. The schoolchildren took part in a ‘Battle’ quiz with host Jason Leong to ‘defeat’ Mr. Dengue, to the delight of the invited guests.

The Meet Mr. Dengue, The Unwanted Guest roadshow will be held at the Blue Concourse at Sunway Pyramid Mall from 12pm Friday 14th October to Sunday 16th October. The highlight of the roadshow is a Pac-Man-styled maze specially designed to be a training course for participants to equip themselves with tools to combat dengue. They will need to collect these tools and avoid being caught by Mr. Dengue’s ‘mosquitoes’ who will act as ‘ghosts’ in the Pac-Man-styled game. Learn fast, complete the course without ‘meeting’ Mr. Dengue’s minions and win special Mr. Dengue premiums! The public can also learn how to build their own mosquito traps as well as identify mosquito breeding areas in a home as part of the planned activities to encourage you and your family to practice good dengue prevention habits.
Head to www.facebook.com/mymrdengue and ‘like’ the page to receive dengue awareness and prevention information on your Facebook timeline. Download the ‘Protection Against Dengue’ brochure on the Meet Mr Dengue Tab at the Facebook page to keep up to date on dengue prevention habits.

Additionally, take the Dengue Readiness Quiz at www.denguemissionbuzz.org to find out how prepared you are against the disease
  
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us
                                                                                 

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Previous Post
Next Post

post written by:

0 comments:

Please leave your comment.